Table 2.
Logistic Regression Analysis for 5 Human Leukocyte Antigen Loci in All Patients With Nevirapine-Induced Hypersensitivity
| Locus |
P Value |
||||
|---|---|---|---|---|---|
| All HSR | SJS/TEN | DILI | NIR | HSS | |
| HLA-A | 894 | .015 | .429 | .672 | .135 |
| HLA-B | 111 | .160 | .068 | .478 | .066 |
| HLA-C | 036 | .014 | .179 | .489 | .564 |
| HLA-DQB1 | 002* | .003* | .006 | .148 | .030 |
| HLA-DRB1 | 137 | .123 | .018 | .455 | .477 |
P values are derived from a likelihood ratio test comparing a logistic regression model both with and without a covariate representing the alleles observed at the genetic locus. Statistically significant findings (P < .05) are indicated in bold while associations withstanding correcting for multiple comparisons (false discovery rate P < .05) are indicated by an asterisk (*).
Abbreviations: DILI, drug-induced liver injury; HLA, human leukocyte antigen; HSR, hypersensitivity reaction; HSS, hypersensitivity syndrome; NIR, nevirapine-induced rash; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.